Research Recommendations For Evofem Biosciences Inc. (EVFM): Here is What You Should Know

Evofem Biosciences Inc. (NASDAQ:EVFM) saw an upside of 6.42% to close Monday at $0.77 after adding $0.05 on the day. The 5-day average trading volume is 3,202,780 shares of the company’s common stock. It has gained $0.8200 in the past week. An average of 2,616,055 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 3,935,796.

EVFM’s 1-month performance is -12.19% or -$0.0979 on its low of $0.7105 reached on 09/29/21. The company’s shares have touched a 52-week low of $0.65 and high of $5.53, with the stock’s rally to the 52-week high happening on 02/17/21. YTD, EVFM has lost -68.07% or -$1.6406. However, the current price is down -86.09%% from the 52-week high price.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Valuation Metrics

Evofem Biosciences Inc. (EVFM) has a trailing price-to-earnings (P/E) ratio of 33.83 for the broader industry and 32.05 for the sector, meaning that investors are optimistic about the stock’s future prospects.EVFM stock has a beta of -0.21. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 35.87 while the price-to-book (PB) in the most recent quarter is 10.99.

Evofem Biosciences Inc.’s quick ratio for the period ended June 29 was 1.20, with the current ratio over the same period at 1.40 meaning that EVFM stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 2.91, while the total debt to equity was 7.83. In terms of profitability, the gross margin trailing 12 months is 46.80%The trailing 12-month EBITDA margin is -22969.28%. The firm’s gross profit as reported stood at $22000.0 against revenue of $0.45 million.

Earnings Surprise

For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected EVFM to announce -$0.37 per share in earnings in its latest quarter, but it posted -$0.27, representing a 27.00% surprise. EBITDA for the quarter stood at more than -$40.87 million. EVFM stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 99.78 million, with total debt at $78.14 million. Shareholders hold equity totaling $155.21 million

Technical Picture

Let’s look briefly at Evofem Biosciences Inc. (EVFM) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 04 October was 49.21% to suggest the stock is trending Neutral, with historical volatility in this time period at 56.05%.

The stock’s 5-day moving average is $0.7394, reflecting a -2.80% or -$0.0222 change from its current price. EVFM is currently trading -11.29% above its 20-day SMA, -38.45% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -13.60% and -62.83% respectively.

Stochastic %K and %D was 25.25% and 14.66% and the average true range (ATR) pointed at 0.0524. The RSI (14) points at 47.48%, while the 14-day stochastic is at 46.20% with the period’s ATR at 0.0543. The stock’s 9-day MACD Oscillator is pointing at -0.0136 and -0.0278 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Evofem Biosciences Inc. (NASDAQ: EVFM), Stifel launched coverage with a Buy rating. Analysts offering their rating for EVFM stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate EVFM as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 2 have offered a “buy” rating.

What is EVFM’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $1.00 and a high of $5.00, with their median price target at $4.00. Looking at these predictions, the average price target given by analysts is for Evofem Biosciences Inc. (EVFM) stock is $3.33.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam